Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) EPS (Weighted Average and Diluted) (2020 - 2025)

Spyre Therapeutics (SYRE) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.74 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 98.69% year-over-year to -$0.74, compared with a TTM value of -$1.98 through Dec 2025, up 98.44%, and an annual FY2025 reading of -$1.98, up 98.44% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.74 for Q4 2025 at Spyre Therapeutics, down from -$0.15 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $40.14 in Q2 2023 and bottomed at -$480.71 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$31.5, with a median of -$0.37 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 6200.0% in 2022, then skyrocketed 14966.67% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$24.33 in 2021, then surged by 182.9% to $20.17 in 2022, then crashed by 2483.29% to -$480.71 in 2023, then surged by 88.22% to -$56.65 in 2024, then surged by 98.69% to -$0.74 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for SYRE at -$0.74 in Q4 2025, -$0.15 in Q3 2025, and $22.86 in Q2 2025.